# Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

> **NCT01079143** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 194 (actual)

## Conditions studied

- Renal Interstitial Fibrosis

## Interventions

- **DRUG:** Certican®
- **DRUG:** Neoral
- **DRUG:** Myfortic
- **DRUG:** Simulect®
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT01079143
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2014-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01079143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01079143, "Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01079143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*